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Mendelian randomizationBackground: To assess whether genetically determined quantitative and qualitative HDL characteristics were in-
dependently associated with coronary artery disease (CAD).
Methods:We designed a two-sample multivariate Mendelian randomization study with available genome-wide
association summary data.We identified genetic variants associatedwithHDL cholesterol and apolipoprotein A-I
levels, HDL size, particle levels, and lipid content to define our genetic instrumental variables in one sample
(Kettunen et al. study, n = 24,925) and analyzed their association with CAD risk in a different study
(CARDIoGRAMplusC4D, n = 184,305). We validated these results by defining our genetic variables in another
database (METSIM, n = 8372) and studied their relationship with CAD in the CARDIoGRAMplusC4D dataset.
To estimate the effect size of the associations of interest adjusted for other lipoprotein traits andminimize poten-
tial pleiotropy, we used the Multi-trait-based Conditional & Joint analysis.
Results:Genetically determinedHDL cholesterol and apolipoprotein A-I levelswere not associatedwith CAD.HDL
mean diameter (β= 0.27 [95%CI = 0.19; 0.35]), cholesterol levels in very large HDLs (β= 0.29 [95%CI = 0.17;
0.40]), and triglyceride content in very largeHDLs (β=0.14 [95%CI=0.040; 0.25])were directly associatedwith
CAD risk, whereas the cholesterol content in medium-sized HDLs (β=−0.076 [95%CI = -0.10;−0.052]) was
inversely related to this risk. These results were validated in the METSIM-CARDIoGRAMplusC4D data.
Conclusions: Some qualitative HDL characteristics (related to size, particle distribution, and cholesterol and
triglyceride content) are related to CAD risk while HDL cholesterol levels are not.
© 2020 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license (http://
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The inverse association between high-density lipoprotein cholesterol
(HDL-C) levels and the risk of coronary artery disease (CAD) has been re-
ported in observational studies [1]. However, experimental and genetic
studies question the causality of this association. On the one hand,
drugs such as fibrates, niacin, and cholesteryl ester transfer protein inhib-
itors increase HDL-C levels but do not decrease CAD risk [2]. On the other
hand, genetic predisposition to high HDL-C levels has not been linked to
any decrease in the risk of cardiovascular events [3,4]. Thus, researchers
are looking beyond HDL-C levels to disentangle this apparent contradic-
tion. Anti-atherogenic properties of HDL particles seem to be determined
by the quality or function of the lipoprotein [5]. HDL particle size and
number have been linked to cardiovascular risk [6], and this association
could be mediated through HDL functionality, which is predictive of car-
diovascular risk [7]. The interplay between HDL-C and triglyceride levels,
as two of the faces of atherogenic dyslipidemia, may also play a relevant
role in their relationship with CAD [8,9]. Thus, further evidence of causal
association between HDL characteristics and CAD risk would provide rel-
evant data on the validity of these particles as therapeutic targets.
Mendelian Randomization (MR) studies have arisen as a powerful
tool to ascertain the potential causality of the association between a bio-
marker and a disease [10]. These studies assess the association between
the genetically determined lifelong values of a biomarker and the devel-
opment of a clinical outcome. MR studies have already raised serious
doubts on the causal role of quantitative HDL characteristics, such as
HDL-C and apolipoprotein A-I (ApoA-I) levels, in CAD [3,11]. However,
to date, the association between qualitative HDL characteristics and
CAD has not been tested using a MR approach. HDL mean diameter,
the concentration of HDL particles of each size subtype, the distribution
of cholesterol across the HDL size subtypes, and the presence of other
lipids in HDL particles (such as triglycerides, highly present in large
HDLs) are some of these qualitative traits. Additionally, this evaluation
must take into account the complexity of lipid metabolism and its po-
tential genetic pleiotropic effects. HDL-C, low-density lipoprotein cho-
lesterol (LDL-C), and triglyceride levels are highly interdependent and,
therefore, themethod used to test the association between HDL proper-
ties and CAD risk should take into account this inter-correlation [12].
This study had two aims: 1) to assess the potential causal association
of quantitative and qualitativeHDL characteristicswithCAD risk, using a
two-sample MR approach; and 2) to explore potential mechanisms
explaining the observed associations.
2. Methods
2.1. Study design and data sources
Wedesigned a two-sampleMR study using aggregated summary data
[10] from three published meta-analyses of genome-wide association
studies. The main analysis was based on data from Kettunen et al. [13]
(n = 24,925) and the CARDIoGRAMplusC4D consortium [14] (n =
184,305), and the validation analysis used the METSIM [15] (n= 8372)
and the CARDIoGRAMplusC4D datasets. Regarding the GWASs on lipo-
protein traits, we used the Kettunen et al. and the METSIM studies be-
cause these are the only ones with publicly available summary data.
Regarding CARDIoGRAMplusC4D, we selected it because it had several
quality characteristics that made it stand out among all GWAS on CAD
with publicly available summary results: a large number of total partici-
pants (n= 184,305), a large number of CAD cases (n= 60,801), a large
number of genetic variants analyzed (8.6 million), and a quite consistent
definition of CAD in the participant studies. Amore detailed description of
the studies is available in Supplementary materials.
We centered our analysis on the genetic variants associated with:
1) the main lipid profile traits in serum (HDL-C, LDL-C, and triglyceride
levels); 2) othermeasurements of HDL quantity (ApoA-I levels); 3) HDL
mean diameter; 4) the quantities of cholesterol transported in small,medium-sized, large and very large HDLs; 5) the quantity of other
lipid species in HDL particles (triglycerides transported in very large
HDLs); and 6) the levels of HDL particles according to the previous
HDL size subtypes. Both the Kettunen et al. and the METSIM studies
measured HDL qualitative characteristics by the same nuclear magnetic
resonance spectroscopy technique [16].
2.2. Assessment of genetic variants linked to lipoprotein characteristics and
CAD risk adjusted for other lipoprotein traits: Multi-trait-based Conditional
& Joint analyses
To identify the genetic variants associated with each lipoprotein char-
acteristic thatwere also linked to CAD considering the potential pleiotropy
among lipid profile traits, we used the Multi-trait-based Conditional &
Joint analysis [17] in both the main and the validation stage. This method
enables the estimation of themagnitude of the association of each genetic
variant with each lipoprotein characteristic and with CAD, independently
from the other genetically determined lipoprotein traits (adjusted effect
sizes). For example, if we considered HDL-C as “main variable” and
LDL-C and triglyceride levels as “covariates”, we would obtain the betas
and standard errors of the associations of genetic variants with
(1) HDL-C (using the Kettunen and METSIM raw summary data) and
(2) CAD (using the CARDIoGRAMplusC4D rawsummary results), adjusted
for the association of these same genetic variants with LDL-C and triglyc-
eride concentrations. For this purpose, we defined sixmultivariatemodels
a priori. Model 1 included HDL-C, LDL-C and triglyceride levels. Further
models included the elements in Model 1 as covariates and the following
parameters as main variables: ApoA-I levels (Model 2); HDL mean diam-
eter (Model 3); the cholesterol content in each HDL size subtype (small,
medium-sized, large, and very large HDL particles; Model 4); the levels
of HDL particles of each size subtype (Model 5); and the triglyceride con-
tent in very large HDLs (Model 6). In model 4 and 5, we required for the
presence of at least two of the HDL subtypes (small, medium-sized,
large, and very large) traits to build the model.
The genetic correlation between traits was estimated by linkage dis-
equilibrium score regressions using all genetic variants.
2.3. Mendelian randomization analyses
Based on the adjusted gene variant effects and their standard errors
computed as previously described, we performed theMR analysis using
the Generalized Summary-data-based Mendelian Randomization
method [18]. The genetic variants to be considered were selected with
the following criteria: 1) strong association with the lipid traits of inter-
est (p-value<5·10−8); 2) not in linkage disequilibrium (R2 < 0.01,
using the 1000 Genome project data – http://www.1000genomes.org/
phase-3-structural-variant-dataset – as reference [19]); and 3) a
minor allele frequency ≥ 0.05.
As an additional approach to exclude potential pleiotropy, we also
removed the variants with a significant result in the HEIDI-outlier test
(p-value<0.01). Finally, we explored and confirmed the exclusion of po-
tential pleiotropic effects using Egger regressions [20]. Statistical signif-
icance of our results was corrected formultiple comparisons (p-value=
0.05/number of traits). A description of complementary sensitivity
analyses using other MR analyses methods such as the median-based
and inverse variance weighted, using the Global Lipid Genetic Consor-
tium dataset [21] and post-hoc statistical power estimations [22] is
available in Supplementary materials.
3. Results
3.1. Mendelian randomization results
3.1.1. Selected genetic variants
We identified genetic variants significantly associated with 13 lipo-
protein characteristics in the data published by Kettunen et al. and
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iants for each lipoprotein trait ranged from 6 (level of medium-sized
HDL particles) to 22 (ApoA-I). Genetic variants included in the analyses
and their unadjusted and adjusted effects are listed in Supplementary
Excel File 1.
We observed high inverse genetic correlations (correlation coeffi-
cient ≤ −0.50) between triglyceride and HDL-C levels. Conversely, we
observed very high direct genetic correlations (correlation coefficient
≥ 0.70) between the cholesterol content in each HDL size subpopulation
and HDL-C concentrations, between HDL mean diameter and the level
of very large HDL particles, and between ApoA-I and the level of very
large HDL particles and their cholesterol content (Supplementary
Fig. 1).
3.1.2. Main analysis
We defined as statistically significant those associations with a p-
value<3.85·10−3 (0.05/13). We observed a direct association between
CAD risk and genetically determined levels of LDL-C (β= 0.26 [95%
Confidence Interval]: [0.17; 0.35], p-value = 1.32·10−8) and triglycer-
ides (β=0.18 [0.073; 0.29], p-value= 1.05·10−3). Conversely, the ge-
netically determined concentrations of HDL-C (β = 0.008 [−0.084;
0.099], p-value = 0.871) or ApoA-I (β = 0.060 [−0.015; 0.13],
p-value = 0.116) were not associated with CAD risk (Figs. 1, 2A and B).
In qualitative HDL measurements, the genetically determined HDL
mean diameter was directly associated with CAD risk (β= 0.27 [0.19;
0.35], p-value = 2.23·10−11) (Figs. 1 and 2C). Cholesterol levels in
very large HDLs was also positively linked to CAD risk (β = 0.29
[0.17; 0.40], p-value = 8.90·10−7), whereas cholesterol in medium-
sized HDLs was inversely related to this risk (β = −0.076 [−0.10;
−0.052], p-value = 4.55·10−11) (Figs. 1, 2D, and E). The geneticallyFig. 1. Association of the genetically determined lipid profile and HDL characteristics with cor
cholesterol (LDL-C) and triglyceride levels (Panel 1), apolipoprotein A-I concentrations (Pane
4), number of particles of each HDL size subtype (Panel 5), and triglyceride levels in very larg
of classic lipid profile parameters. In all cases, main Mendelian randomization analyse
CARDIoGRAMplusC4D) appear below. NA: non-available association.determined levels of all subtypes of HDL particles showed an inverse
trend towards an association with CAD risk, but only that between
very large HDLs and CAD was statistically significant (β = −0.22
[−0.32;−0.12], p-value = 7.12·10−6) (Fig. 1). Finally, the genetically
determined levels of triglycerides in very large HDLs were directly
related to CAD risk (β = 0.14 [0.040; 0.25], p-value = 6.84·10−3)
(Figs. 1 and 2F). Effect sizes of all the associations are available in Sup-
plementary Table 1.
Genetic variants linked to both HDL qualitative traits and CAD risk
were located within LIPC, the APOE/C1/C4/C2 cluster, PCIF1, TTC39B,
and APOB (Supplementary Excel File 1).
3.1.3. Validation analysis
In the validation analysis (Fig. 1), we confirmed the direct associa-
tion between the genetically determined concentrations of LDL-C and
CAD risk (β= 0.24 [0.17; 0.31], p-value = 1.21·10−10), triglycerides
and CAD risk (β= 0.084 [0.013; 0.15], p-value = 0.020), and the null
link between the genetically determined HDL-C levels and CAD (β=
−0.025 [−0.087; 0.036], p-value = 0.419).
Results regarding qualitative HDL traits were also replicated. We
confirmed the direct association of genetically determined HDL mean
diameter with CAD risk (β= 0.34 [0.23; 0.46], p-value = 4.47·10−9).
There was a positive link between the cholesterol content in large
HDLs and CAD (β=0.45 [0.34; 0.55], p-value= 1.61·10−16) and an in-
verse relationship between the genetically determined cholesterol
levels in medium-sized HDLs and CAD risk (β = −0.46 [−0.55;
−0.37], p-value = 5.9·10−23). Finally, high genetically determined
levels of triglycerides in very large HDLs were nominally associated
with greater CAD risk (β = 0.081 [0.008; 0.15], p-value = 0.030)
(Fig. 1 and Supplementary Fig. 2). We could not assess the associationsonary artery disease risk. Effect of genetically determined HDL cholesterol (HDL-C), LDL
l 2), mean HDL diameter (Panel 3), cholesterol content in each HDL size subtype (Panel
e HDLs (Panel 6) on CAD, independently from the effect of genetically determined levels
s (Kettunen-CARDIoGRAMplusC4D) appear first and the validation ones (METSIM-
Fig. 2. Association of individual SNPs affecting lipoprotein traits with coronary artery disease risk in the main analysis. Estimates of the associations of individual SNPs related to (A) HDL cholesterol (HDL-C) levels, (B) apolipoprotein A-I
concentrations, (C) mean HDL diameter, (D) cholesterol content in medium-sized HDLs, (E) cholesterol content in very large HDLs, and (F) triglyceride levels in very large HDLs with coronary artery disease risk. Estimates were derived from the
study by Kettunen et al. and the CARDIoGRAMplusC4D meta-analyses (multivariate adjusted estimates). Error bars represent 95% confidence intervals. The slopes of the lines show the genetic instrumental variable regression estimates of the
effect of the lipid characteristics on coronary artery disease risk.
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variants associated with at least two of these HDL traits in the
METSIM study. The effect sizes of all the associations of interest are
available in Supplementary Table 2.
3.1.4. Sensitivity analysis
Egger regression intercept estimates supported the absence of pleio-
tropic effects. Results of the median-based and inverse variance
weighted methods confirmed the direction and significance of the
main analyses (Supplementary Table 3).
Associations between genetically determined HDL-C, LDL-C and
triglyceride levels and CAD risk identified in our main analysis were
similar to those obtained from the Global Lipid Genetic Consortium
(Supplementary Table 4).
3.1.5. Post-hoc statistical power estimation
Power estimation for the main analyses ranged from 2.4% to 96.9%
(Supplementary Table 5).
4. Discussion
Ourfindings suggest a potential causal relationship between qualita-
tive HDL characteristics and CAD risk, even though HDL-C and ApoA-I
levels were not associated with CAD. In particular, genetically deter-
mined mean HDL size, the distribution of cholesterol across HDL size
subpopulations, and the triglyceride content in HDL particles were
related to CAD risk.
The relationship between HDL and cardiovascular risk is controver-
sial [4]. Recent studies suggest that HDL functions and quality character-
istics, rather than HDL-C concentration, are the main determinants of
HDL anti-atherogenic properties [5]. Our data are consistent with previ-
ous evidence, and reflect that HDL-C and ApoA-I levels in the blood-
stream are not causally related to CAD [3,11]. However, we observed a
decrease in CAD risk when HDL-C was mainly transported in smaller
HDLs, but an increase in CAD risk when HDL-C was carried by larger
HDL particles (in both main and validation analyses, there is a gradient
towards greater CAD risk as more cholesterol is transported in larger
HDLs). The protective effect of cholesterol content in medium-sized
HDLs and the increase in CAD risk due to cholesterol levels in larger
particles observed in our data may contribute to explaining why the
overall HDL-C levels are not causally associated with cardiovascular
risk [3,11]. Our results could also help explain the therapeutic failure
of the pharmacological agents known to increase HDL-C levels. Niacin
or cholesteryl ester transfer protein inhibitors are effective in increasing
HDL-C concentrations but not in reducing CAD risk [2]. This paradox
could be explained by the promotion of the accumulation of cholesterol
content in large HDLs after the use of these drugs [23,24]. In gemfibrozil-
treated patients, changes in HDL-C levels accounted for a small proportion
of the CAD risk reduction (<10%),whereas the increase in small HDLswas
much more predictive of this risk reduction [25]. Finally, our results also
concurwith genetic studies analyzing variants in the SR-B1 gene, showing
that individuals with loss-of-function variants have higher HDL-C concen-
trations, mainly in very large particles, but also higher CAD risk [26].
However, there is still controversy in the relationship between
HDL size subtypes and cardiovascular risk: some authors advocate
for small HDLs as indicators of lower CAD risk [27] while others sug-
gest they are associated with increased CAD risk [28]. There are sev-
eral possible explanations for this heterogeneity. First, baseline
health conditions of the subjects affect HDL quality and function.
Lipid-poor, protein-rich, small HDLs could be dysfunctional in
pro-oxidative and pro-inflammatory pathological states due to
post-translational modifications of their proteins and their enrich-
ment in pro-inflammatory mediators (such as serum amyloid A or
complement 3) [29]. Second, laboratory procedures to measure
HDL size (nuclear magnetic resonance spectroscopy, electrophore-
sis, etc.) differed between the published studies, and there is lowconcordance between these techniques [30]. Third, the statistical
models used did not consider all the same confounding factors and
did not always include as covariates the levels of HDL-C or other
lipid profile parameters related to these lipoproteins (e.g. triglycer-
ide concentrations).
Triglyceride andHDL-C levelsmay be two sides of the same coin, and
this relationship may contribute to explaining why HDL-C is not caus-
ally related to CAD while triglycerides are. Hypertriglyceridemic states
(generally due to high levels of very-low density lipoprotein concentra-
tions in plasma) are linked to an increased activity of the cholesteryl
ester transfer protein, an enzyme that exchanges triglycerides in very-
low density lipoproteins for cholesterol in HDLs, resulting in an enrich-
ment of HDLs in triglycerides [8]. Aged HDL particles may also become
increasingly richer in triglycerides because this exchange is an essential
process by which HDLs get rid of the cholesterol they have collected
from peripheral cells and transfer it back to the liver [31]. In any case,
triglyceride-rich HDLs have been shown to present their ApoA-I in
an unstable conformation [32], which may be related to lower HDL
function (lower cholesterol efflux capacity) and a greater disintegra-
tion of the HDL structure (lower HDL-C levels) [8]. Our results con-
firm that triglyceride-rich HDLs are causally related to higher CAD
risk independently from the circulating levels of triglycerides and
HDL-C. In addition, this mechanism also verifies the hypothesis
that high triglycerides (in circulation and in HDL particles) are es-
sential mediators of high cardiovascular risk and suggests that low
HDL-C levels in these states may be a secondary consequence of
this lipid disruption.
Both observational and experimental studies havemore consistently
found an inverse relationship between the number of HDL particles and
cardiovascular risk, compared to HDL-C levels [7]. Similarly, we ob-
served that the concentrations of HDL particles of all sizes were in-
versely related to CAD risk, although only the genetically determined
levels of very large HDLs were significantly associated with it in the
main analysis. Unfortunately, we could not validate these results due
to the lack of valid genetic variants in the METSIM study.
Our results are mechanistically plausible and highlight novel poten-
tial therapeutic targets in cardiovascular disease, since genetic variants
individually associated with HDL qualitative traits and CAD in our data
were locatedwithin several HDL-related genes or gene clusters. LIPC en-
codes for hepatic lipase C, an enzyme that hydrolyzes triglycerides in
circulating lipoproteins, including HDL particles [31]. Hydrolysis of
HDL triglycerides by this enzyme generates small/medium-sized,
triglyceride-depleted particles, considered to be more stable and func-
tional than very large, triglyceride-rich HDLs [33]. Since triglyceride-
rich HDLs were also causally linked to CAD in our data, this potential
mechanismwould contribute to explaining a decrease in cardiovascular
risk. The APOE/C1/C4/C2 cluster encodes apolipoproteins E, C-I, C-II, and
C-IV and has been classically associatedwith blood lipid levels [34]. Par-
ticularly, apolipoprotein E is a pivotal mediator in reverse cholesterol
transport [35] and apolipoprotein C-I is involved in the activation of
lecithin-cholesterol acyltransferase and the inhibition of cholesteryl
ester transfer protein, two key enzymes in HDL metabolism [36,37].
The third most relevant HDL-related locus encodes the PDX1 C-
Terminal Inhibiting Factor 1 (PCIF1) and is located next to the PLTP
gene, which expresses the phospholipid transfer protein, an enzyme
involved in HDL remodeling/stabilization [31]. PCIF1-related gene
variants have been shown tomodulate phospholipid transfer protein
function in other studies [38]. Finally, TTC39B encodes the tetratrico-
peptide repeat domain protein 39B, whose genetic variants had al-
ready been associated with HDL-C levels and CAD in previous
works [34,39].
Our study presents some limitations. First, in order to use a MR ap-
proach, we had to make some assumptions [10], among which stands
out the absence of pleiotropy. In our case, most of the genetic variants
used as instruments were associated with more than one lipid trait. To
solve this problem, we used a novel approach (Multi-trait based
6 A. Prats-Uribe et al. / Metabolism Clinical and Experimental 112 (2020) 154351Conditional & Joint analysis–Generalized Summary data-based Mende-
lian randomizationmethodology) to control for the confounding effects
related to the close relationship between lipoprotein characteristics and
to minimize pleiotropy [17]. Second, the interpretation of multivariable
MR is challenging, especially when the covariate-biomarker lies on the
causal pathway from the main-biomarker to disease, or when the
covariate-biomarker measures the same entity as the main-biomarker
[40]. Third, the population testedmay exhibit significant genetic hetero-
geneity because of different ethnic origin. The Kettunen et al. study
included European populations, the CARDIoGRAMplusC4D study in-
cluded European andAsianpopulations, but theMETSIMstudy included
only Finnish. However, this heterogeneity is assumed to be minimal
since the original GWASs excluded those genetic variants whose allele
frequencies departed fromHardy-Weinberg equilibriumand all the var-
iants included in our analyses, except rs73168081 (associatedwith cho-
lesterol content in large HDL particles in Kettunen et al), presented a
similar allele frequency in the threeGWASs considered (Supplementary
Excel File 1). In addition, the METSIM study only considered male
population, and this may have partially distorted the findings of the val-
idation analyses. Nevertheless, sex- and age-related bias had been orig-
inally addressed in the original GWASs as described in theMethodology
section of each of the studies. Fourth, we have not been able to study
whether other HDL functional properties (such as cholesterol efflux ca-
pacity, HDL antioxidant properties, and HDL particle type according to
ApoA-I and ApoA-II content) are causally linked to CAD due to unavail-
ability of GWAS studies on these traits with publicly available summary
data. Fifth, the statistical power of our analyses was limited for some of
the traits of interest. Finally, in the validation analysis we could not gen-
erate genetic instrumental variables for some of the lipoprotein traits.
However, our study has several methodological strengths. First, our re-
sults are based in MR, a useful approach to explore the causality of the
association between biomarkers and specific diseases. Second, we in-
cluded two independent MR analyses to validate the results initially
observed. Finally, the validity of the genetic variants for HDL-C, LDL-C
and triglyceride levels initially generated was confirmed, supporting
the validity of these datasets for the analysis of other genetic variants.
5. Conclusions
Several genetically and life-long qualitative HDL characteristicswere
related to CAD risk. AlthoughHDL-C andApoA-I levelswere not causally
linked to CAD, our results support a potential causality between higher
mean HDL diameter, greater cholesterol levels in very large HDLs, and
triglyceride-rich HDL particles and higher CAD risk, and between
cholesterol levels in medium-sized HDLs and lower CAD risk. This rela-
tionship could be mediated by several HDL-related proteins, which are
suggested as potential therapeutic targets for further exploration in
cardiovascular prevention.
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